Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model

International Journal of Cancer

Volumn 138, Issue 11, 2016, Pages 2665-2677

  Sudhan, Dhivya R ^a   Pampo, Christine ^a   Rice, Lori ^a   Siemann, Dietmar W ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

bone resorption; cathepsin L; KGP94; metastasis; prostate cancer

Indexed keywords

3 BROMOPHENYL 3 HYDROXYPHENYL KETONE THIOSEMICARBAZONE; CATHEPSIN L; CYSTEINE PROTEINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG; KGP94; THIOSEMICARBAZONE DERIVATIVE; THIOUREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR; SECONDARY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; CATHEPSIN L; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MICE; NEOPLASM METASTASIS; OSTEOCLASTS; PROSTATIC NEOPLASMS; THIOSEMICARBAZONES; THIOUREA; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957654886     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29992     Document Type: Article

References (50)

1. Siegel RL, Miller KD, Jemal A., Cancer statistics, 2015. CA: Cancer J Clin 2015; 65: 5-29.
2. Norgaard M, Jensen AO, Jacobsen JB, et al., Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184: 162-7.
3. Soloway MS, Hardeman SW, Hickey D, et al., Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
4. Carlin BI, Andriole GL., The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-94.
5. Palermo C, Joyce JA., Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 2008; 29: 22-8.
6. Lankelma JM, Voorend DM, Barwari T, et al., Cathepsin L, target in cancer treatment? Life Sci 2010; 86: 225-33.
7. Chauhan SS, Goldstein LJ, Gottesman MM., Expression of cathepsin L in human tumors. Cancer Res 1991; 51: 1478-81.
8. Barrett AJ, Kirschke H., Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol 1981; 80(Pt C): 535-61.
9. Gal S, Willingham MC, Gottesman MM., Processing and lysosomal localization of a glycoprotein whose secretion is transformation stimulated. J Cell Biol 1985; 100: 535-44.
10. Stearns NA, Dong JM, Pan JX, et al., Comparison of cathepsin L synthesized by normal and transformed cells at the gene, message, protein, and oligosaccharide levels. Arch Biochem Biophys 1990; 283: 447-57.
11. Gocheva V, Zeng W, Ke D, et al., Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006; 20: 543-56.
12. Goretzki L, Schmitt M, Mann K, et al., Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 1992; 297: 112-8.
13. Everts V, Korper W, Hoeben KA, et al., Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 2006; 21: 1399-408.
14. Laurent-Matha V, Derocq D, Prebois C, et al., Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. J Biochem 2006; 139: 363-71.
15. Sudhan DR, Siemann DW., Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clin Exp Metastasis 2013; 30: 891-902.
16. Cuvier C, Jang A, Hill RP., Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin Exp Metastasis 1997; 15: 19-25.
17. Thomssen C, Schmitt M, Goretzki L, et al., Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res 1995; 1: 741-6.
18. Xu X, Yuan G, Liu W, et al., Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance. Exp Oncol 2009; 31: 102-5.
19. Kakegawa H, Tagami K, Ohba Y, et al., Secretion and processing mechanisms of procathepsin L in bone resorption. FEBS Lett 1995; 370: 78-82.
20. Tagami K, Kakegawa H, Kamioka H, et al., The mechanisms and regulation of procathepsin L secretion from osteoclasts in bone resorption. FEBS Lett 1994; 342: 308-12.
21. Roodman GD., Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64.
22. Kumar GD, Chavarria GE, Charlton-Sevcik AK, et al., Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett 2010; 20: 6610-5.
23. Chavarria GE., Kinetic characterization of Thiosemicarbazone as cysteine protease inhibitors and their potential use as therapeutic agents against metastatic cancer and Chagas disease. Waco, Texas: Baylor University, 2012.
24. Wang M, Stearns ME., Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. Differentiation 1991; 48: 115-25.
25. Siemann DW, Norris CM, Ryan A, Shi W., Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA;ZD6474). Anticancer Res 2009; 29: 1987-92.
26. Bubendorf L, Schopfer A, Wagner U, et al., Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-83.
27. Raggatt LJ, Partridge NC., Cellular and molecular mechanisms of bone remodeling. J Biol Chem 2010; 285: 25103-8.
28. Sudhan DR, Siemann DW., Cathepsin L targeting in cancer treatment. Pharmacol Ther 2015; 155: 105-16.
29. Leventis AK, Shariat SF, Kattan MW, et al., Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001; 19: 1030-9.
30. Fizazi K, Carducci M, Smith M, et al., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22.
31. Fournier PG, Stresing V, Ebetino FH, et al., How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia 2010; 12: 571-8.
32. Zheng X, Chu F, Chou PM, et al., Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol 2009; 296: C65-74.
33. Leto G, Sepporta MV, Crescimanno M, et al., Cathepsin L in metastatic bone disease: therapeutic implications. Biol Chem 2010; 391: 655-64.
34. Gianotti A, Sommer CA, Carmona AK, et al., Inhibitory effect of the sugarcane cystatin CaneCPI-4 on cathepsins B and L and human breast cancer cell invasion. Biol Chem 2008; 389: 447-53.
35. Kirschke H, Eerola R, Hopsu-Havu VK, et al., Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur J Cancer 2000; 36: 787-95.
36. Turk V, Turk B, Turk D., Lysosomal cysteine proteases: facts and opportunities. Embo J 2001; 20: 4629-33.
37. Kishore Kumar GD, Chavarria GE, Charlton-Sevcik AK, et al., Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett 2010; 20: 1415-9.
38. Chung JH, Im EK, Jin TW, et al., Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration. Exp Mol Med 2011; 43: 179-88.
39. Rebbaa A, Chu F, Sudha T, et al., The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor. Anticancer Res 2009; 29: 4473-81.
40. Coleman RE, Major P, Lipton A, et al., Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-35.
41. Leto MC, Flandina C, Sepporta MV, et al., Cathepsin L in Normal and Pathological Bone Remodeling. Clin Rev Bone Miner Metab 2011; 9: 109-21.
42. Yoneda T, Hiraga T., Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005; 328: 679-87.
43. Furuyama N, Fujisawa Y., Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts. Steroids 2000; 65: 371-8.
44. Potts W, Bowyer J, Jones H, et al., Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy. Int J Exp Pathol 2004; 85: 85-96.
45. Woo JT, Yamaguchi K, Hayama T, et al., Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo. Eur J Pharmacol 1996; 300: 131-5.
46. Yasuma T, Oi S, Choh N, et al., Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption. J Med Chem 1998; 41: 4301-8.
47. Le Gall C, Bonnelye E, Clezardin P., Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2008; 2: 218-22.
48. Leung P, Pickarski M, Zhuo Y, et al., The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 2011; 49: 623-35.
49. Zhang J, Dai J, Qi Y, et al., Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235-44.
50. Pfeilschifter J, Diel IJ., Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 1570-93.